| 51.30 Data as of May 20 |  -0.70 / -1.35%Today’s Change | 39.85 Today|||52-Week Range 52.45 | +8.13% Year-to-Date |
| Good News for Roche's Tarceva - Analyst Blog May 16 / Zacks.com | Narrower-Than-Expected Loss at Rigel Pharma - Analyst Blog May 09 / Zacks.com |
| Wider-than-Expected Loss at Optimer - Analyst Blog May 10 / Zacks.com | Will DENTSPLY Beat Earnings in 1Q? - Analyst Blog May 08 / Zacks.com |
| Previous close | 52.00 |
| Today’s open | 51.30 |
| Day’s range | 51.30 - 51.30 |
| Volume | 32,655 |
| Average volume (3 months) | 1,965 |
| Market cap | $65.1B |
| Dividend yield | 6.07% |
| Earnings growth (last year) | -32.02% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -16.72% |
| P/E ratio | -- |
| Price/Sales | 2.14 |
| Price/Book | 2.73 |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $28.0B |
| Annual profit (last year) | $6.3B |
| Net profit margin | 22.51% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Pascal Soriot, PhD, MBA |
EVP-Global Operations & Information Services David Smith |
Corporate headquarters London, London & South East |
.
